Rapidly Progressive Triple M Overlap Syndrome After Immune Checkpoint Inhibitor Therapy
Cureus · 12.07.2026
DOI: 10.7759/cureus.112508 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cureus, erschienen am 12.07.2026. Verfasst von Seth Garrett und 6 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, Henry Ford Health System, Detroit, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) are widely used in cancer treatment, but can cause immune-related adverse events affecting multiple organ systems. Triple M overlap syndrome (TMOS) is a rare and often fatal complication, consisting of the triad of ICI-mediated myositis, myocarditis, and myasthenia gravis. An 85-year-old man with metastatic renal cell carcinoma was initiated on combination ICI-based therapy with pembrolizumab and lenvatinib. Approximately four weeks after initiation of immunotherapy, he presented to the emergency department following a two-week history of progressive neck extensor weakness, downward gaze, worsening proximal upper and lower extremity weakness, recurrent falls, dysphagia, and dysphonia. On evaluation, myositis, myocarditis, and clinical evidence of a myasthenia gravis-like syndrome were noted, and TMOS was diagnosed. Initial treatment with high-dose intravenous corticosteroids and intravenous immunoglobulin was started, yet the patient's condition deteriorated. Despite aggressive treatment, due to hemodynamic instability and liver injury, he could not be started on plasmapheresis or second-line immunosuppression. With progressive multiorgan failure, the patient's management was shifted to comfort-based measures. Although an increasing number of immunosuppressive agents have shown efficacy in TMOS management, this case illustrates how the multiorgan injury inherent to TMOS can itself create contraindications to the very therapies required for definitive treatment. This self-reinforcing cycle of therapeutic limitation highlights the importance of early recognition and aggressive management of TMOS prior to end-organ damage, narrowing the treatment window.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Internal Medicine, Henry Ford Health System, Detroit, USA.
- Rheumatology, Henry Ford Health System, Detroit, USA.
- Internal Medicine, Henry Ford Macomb Hospital, Clinton Township, USA.
Zitieren
APA
Garrett, S., Ansari, A., Siddada, S., Sankar, S., Bishnoi, A., Meysami, A., & Hussain, S. (2026). Rapidly Progressive Triple M Overlap Syndrome After Immune Checkpoint Inhibitor Therapy. Cureus. https://doi.org/10.7759/cureus.112508
Vancouver
Garrett S, Ansari A, Siddada S, Sankar S, Bishnoi A, Meysami A, et al. Rapidly Progressive Triple M Overlap Syndrome After Immune Checkpoint Inhibitor Therapy. Cureus. 2026. doi:10.7759/cureus.112508
BibTeX
@article{Garrett2026,
author = {Garrett, Seth and Ansari, Anam and Siddada, Sruthi and Sankar, Shobana and Bishnoi, Amita and Meysami, Alireza and Hussain, Sufiya},
title = {Rapidly Progressive Triple M Overlap Syndrome After Immune Checkpoint Inhibitor Therapy},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.112508}
}
EUVIMED